

# ADESHWAR MEDITEX LIMITED

A + MEDITEX™



ISO13485-2016 CERTIFIED COMPANY

(Previously Known As Adeshwar Meditex Pvt. Ltd.)

Manufacturer & Exporter of Sterile Wound Dressings, Medical Disposables, First Aid Kits, Pharmaceuticals Etc.

Regd. Office: 68, Atlanta Bldg. J.B. Marg, Nariman Point, Mumbai-400002, Maharashtra, India.

Tel.: 91-22-22674137/38. Fax: 91-22-22674139

E-mail: adeshwarmedi@gmail.com, compliance@adeshwarmeditex.com

Website: www.adeshwarmeditex.com

CIN: L52390MH2007PLC169544

November 04, 2022

To,

Asst. General Manager-

Dept of Corp. Services,

BSE Ltd.

1st Floor, P.J. Towers, Dalal Street,

Fort, Mumbai: 400001.

Respected Sir,

**Sub: Outcome of the Board Meeting held on Friday, November 04, 2022.**

With reference to the above captioned subject, we wish to intimate your esteemed exchange that as decided in the Meeting of the Board of Directors of the Company held today, i.e. on November 09, 2022, for which intimation was already given to you, the Board of Directors has:

1. Considered and approved the appointment of Mr. Shailesh Vinayak Rajpure (DIN: 06758460) as an Additional Director (Executive) of the Company;
2. Taken on record the Standalone and Consolidated Unaudited (Provisional) Financial Results of the Company for half year ended September 30, 2022, along with the Limited Review Report;
3. Considered and approved closure of Adeshwar Meditex Ltd-FZCO, Wholly owned subsidiary of the company.

In connection with Point No. 2, please find enclosed the copy of Standalone and Consolidated Unaudited (Provisional) Financial Results of the Company for half year ended September 30, 2022 along with Limited Review Report by the Statutory Auditors of the Company as "Annexure-I".



Factory: 17-18, Dewan & Sons Udyog Nagar, Palghar (West) 401  
404. (M.S.) India Tel.: +91-2525-252058/250687. Cell No.: +91-  
9223487040/9325015511.



The meeting of Board of Directors held today at 01:00 pm (IST) and concluded at 05.12 pm (IST).

The above intimation is given to you for your record.

Thanking You,  
Yours faithfully,  
**For Adeshwar Meditex Limited**



**Shivani Tiwari**  
**Company Secretary and Compliance Officer**  
**Mem No: A54854**

*Encl: as above*



# J N GUPTA & CO

Chartered Accountants

1505, Bianca Apartment, Gundavali Azad Road,  
Andheri East, Mumbai-400069  
Contact No. 7208358784, 9001893895  
Email: [jnguptaca@icai.org](mailto:jnguptaca@icai.org)



## LIMITED REVIEW REPORT ON UNAUDITED HALF YEARLY STANDALONE FINANCIAL RESULTS OF COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

TO,


**The Board of Directors of  
Adeshwar Meditex Limited,**

We have reviewed the accompanying statement of unaudited financial results of Adeshwar Meditex Limited for the half year ended September 30, 2022, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. This statement- is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagements (RE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized practice and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For M/s J N Gupta & Co.  
Chartered Accountants**

  
Digitally signed by  
Jagdish Narain Gupta  
Date: 2022.11.04  
12:50:40 +05'30'

**CA. Jagdish Narain Gupta  
Partner**

M. No: 400438  
FRN: 006569C  
UDIN: 22400438BCAJMR3122  
Place: Mumbai  
Date: 04<sup>th</sup> November, 2022





**Adeshwar Meditex Limited**

**CIN : U52390MH2007PLC169544**

**Statement Of Unaudited Standalone Financial Results For The Half Year And Year Ended 30th September 2022**

(Rs. in Lakhs)

Particulars	Half Year Ended 30.09.2022 (Unaudited)	Half Year Ended 30.09.2021 (Unaudited)	Year Ended 31.03.2022 (Audited)
Revenue From Operations	4,605.55	3,021.12	6,475.54
Other Income	8.23	2.22	22.90
<b>Total Income</b>	<b>4,613.78</b>	<b>3,023.34</b>	<b>6,498.44</b>
<u>Expenses:</u>			
Cost of Materials Consumed	3,612.54	2,732.33	5,679.94
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	314.07	(208.32)	(190.66)
Employee Benefit Expense	99.33	87.92	215.24
Finance Costs	103.55	101.90	202.63
Depreciation and Amortisation Cost	25.78	16.64	38.20
Other Expenses	307.77	200.68	433.98
<b>Total Expenses</b>	<b>4,463.04</b>	<b>2,931.15</b>	<b>6,379.33</b>
<b>Profit Before Prior Period Items ,Exceptional and Extraordinary Items and Tax</b>	<b>150.74</b>	<b>92.19</b>	<b>119.11</b>
<b>Prior Period Item</b>			
Depreciation	-	-	-
Gratuity	-	-	-
<b>Tax Expense:</b>			
(1) Current Tax	42.00	23.97	39.00
(2) Deferred Tax	-	-	0.82
<b>Profit From The Period</b>	<b>108.74</b>	<b>68.22</b>	<b>79.29</b>
<b>Profit/(Loss) For The period</b>	<b>108.74</b>	<b>68.22</b>	<b>79.29</b>
<b>Earning Per Equity Share:</b>			
Face Value Per Equity Shares Rs.10/- Fully Paid up.			
(1) Basic	0.75	0.54	0.55
(2) Diluted	0.75	0.54	0.59

**For & On Behalf of the Board  
For Adeshwar Meditex Limited**

*Siddharth Talati*

**Siddharth Talati  
Managing Director  
DIN : 01748038  
Date: 04-11-2022**





**Adeshwar Meditex Limited**  
**CIN : U52390MH2007PLC169544**  
**Unaudited Statement of Standalone assets and Liabilities As At 30th Sep, 2022**

(Rs. in Lakhs)

Particulars	30th Sep 2022 (Amount in `)	31st March 2022 (Amount in `)
<b>I. EQUITY AND LIABILITIES</b>		
<b>(1) Shareholder's Funds</b>		
(a) Share Capital	1,443.14	1,443.14
(b) Surplus	1,760.98	1,652.24
<b>(2) Non-current liabilities</b>		
(a) Long-Term Borrowings	308.39	407.14
(b) Other Long Term Liabilities	3.78	12.17
(c) Long Term Provision	33.93	33.93
<b>(3) Current liabilities</b>		
(a) Short-Term Borrowings	1414.85	1,317.33
(b) Trade Payables	-	-
(A) Total Outstanding Dues of Micro Enterprises and Small Enterprises; and	-	-
(B) Total Outstanding Dues of Creditors Other Than Micro Enterprises and Small Enterprises	1,698.70	2,082.71
(c) Other Current Liabilities	204.62	298.99
(d) Short-Term Provisions	28.00	9.53
<b>Total</b>	<b>6,896.39</b>	<b>7,257.18</b>
<b>II. Assets</b>		
<b>(1) Non-Current Assets</b>		
<b>(a) Property, Plant and Equipment and Intangible Assets</b>		
<b>(i) Property, Plant and Equipment</b>		
(iii) Capital work-in-progress	328.08	302.99
(b) Non-Current Investments	10.01	10.01
(c) Long Term Loans and Advances	101.56	89.90
(d) Deferred Tax Asset (Net)	12.31	12.31
(e) Other Non-Current Assets	288.46	332.01
<b>(2) Current Assets</b>		
(a) Inventories	2,230.08	2,530.07
(b) Trade Receivables	3,216.78	3,248.34
(c) Cash and Cash Equivalents	183.00	192.10
(d) Short-Term Loans and Advances	513.13	526.70
(e) Other Current Assets	12.98	12.75
<b>Total</b>	<b>6,896.39</b>	<b>7,257.18</b>

For & On Behalf of the Board  
For Adeshwar Meditex Limited

*Siddharth Talati*

Siddharth Talati  
Managing Director

DIN : 01748038

Date: 04-11-2022





**Adeshwar Meditex Limited**  
**CIN : U52390MH2007PLC169544**  
**Unaudited Standalone Cash Flow Statement For The Period Ended Sep 30, 2022**


(Rs. in Lakhs)

Particulars	For the Period Ended 30th Sep 2022	For the Year ended March 31, 2022
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>		
Net profit before tax and extraordinary items	150.74	119.11
Adjustments for:		
Depreciation and amortisation expense	25.78	38.20
Interest Paid	103.55	191.37
Interest Received	(8.23)	(18.81)
Long Term Provision For Gratuity	-	6.17
Share Issue Expenses	-	10.88
Operating profit / (loss) before working capital changes	<b>271.84</b>	<b>346.93</b>
<b>Changes in working capital:</b>		
Increase / (Decrease) in Inventories	299.99	80.67
Increase / (Decrease) in Payables	(384.01)	288.09
Increase / (Decrease) in Receivables	31.56	(521.85)
Increase / (Decrease) in Short Term Provision	18.47	(4.69)
(Increase) / Decrease in Other current Liabilities	(94.37)	28.20
(Increase) / Decrease in Other Current Assets	(0.23)	31.27
(Increase) / Decrease in Other Non-Current Assets	43.54	(127.30)
Increase / (Decrease) in Short Term Loans and Advances	13.57	(308.69)
	<b>(71.47)</b>	<b>(534.31)</b>
<b>CASH FLOW FROM / (USED IN) OPERATING ACTIVITIES</b>	<b>200.37</b>	<b>(187.38)</b>
Less: Taxes paid	42.00	39.00
Less: Taxes for Earlier Years	-	17.13
<b>NET CASH FLOW FROM / (USED IN) OPERATING ACTIVITIES</b>	<b>158.37</b>	<b>(243.51)</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>		
Purchase of tangible / intangible assets	(50.88)	(117.18)
(Increase) / Decrease in long term loan and advances	(11.66)	(15.60)
(Increase) / Decrease in non-current investments	0.00	(1.40)
Dividend/ bank interest received	8.23	18.81
Investment in WOS	-	(0.21)
<b>NET CASH FLOW FROM / (USED IN) INVESTING ACTIVITIES</b>	<b>(54.31)</b>	<b>(115.57)</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>		
Interest expenses	(103.55)	(191.37)
Changes in Long Term Borrowing	(98.75)	(128.65)
Proceeds from Share Capital	-	975.00
Changes in Short Term Borrowing	97.52	(186.59)
Share Issue Expenses	-	(10.88)
Changes in Other Long Term Liabilities	(8.39)	(13.03)
<b>NET CASH FLOW FROM / (USED IN) FINANCING ACTIVITIES</b>	<b>(113.18)</b>	<b>444.47</b>
<b>NET INCREASE / (DECREASE) IN CASH &amp; CASH EQUIVALENTS (A+B+C)</b>	<b>(9.10)</b>	<b>85.39</b>
<b>Cash and Cash equivalents at beginning period (Refer Note 14)</b>	<b>192.10</b>	<b>106.71</b>
<b>Cash and Cash equivalents at end of period (Refer Note 14)</b>	<b>183.00</b>	<b>192.10</b>
<b>D. Cash and Cash equivalents comprise of</b>		
Cash on hand	0.14	0.88
<b>Balances with banks</b>		
In current accounts	<b>182.86</b>	<b>191.22</b>
<b>Total</b>	<b>183.00</b>	<b>192.10</b>

This Cash Flow Statement has been prepared as per "Indirect Method" as prescribed by Accounting Standard -3 (revised) "Cash Flow Statements"

For & On Behalf of the Board

For Adeshwar Meditex Limited



Siddharth Talati  
Managing Director

DIN : 01748038

Date: 04-11-2022





## Notes

1. The unaudited financial results were reviewed by the Audit Committee and taken on record by the Board of directors at their meeting held on 04th November, 2022.
2. As required under Regulation 33 of the SEBI (LODR) Regulations, 2015, the Statutory Auditors have issued Limited Review Reports on the aforesaid unaudited financial results for the half year ended 30th September, 2022, which were also approved by the Audit Committee and Board at their meeting held on 04th November, 2022.
3. The Earning Per Sare (EPS) has been computed in accordance with the Accounting Standard on Earnings Per Share (AS 20).
4. The company is engaged in the Manufacturer and Trader of Medical Dressings, Bandages, Face Mask and PPE kits.
5. As per MCA Notification dated 16\* February 2015, companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the compulsory requirement of adoption of IND-AS. As the company is covered under the exempted category, it has not adopted IND-AS for preparation of financial results.
6. The company has issued and allotted 39,00,000 equity share of Rs. 10/- each at a price of Rs.25/- per share through an Initial Public Offer aggregating to Rs. 975 lakhs. The net issue proceeds, after excluding Expenses is 933.26 lakhs. The details of utilization of net IPO Proceeds is Mentioned Below,

Particulars	As per Prospectus	Actual Utilization (as on 30.09.2022)	Pending for utilization
Part Repayment of Loans	200.00	200.00	-
Funding Working Capital Requirement	527.00	527.00	-
General Corporate Purpose	206.26	206.26	-
Total	933.26	933.26	-

Figures of Previous year/Period have been regrouped/recast wherever necessary, in order to make comparable.

*Sanjay Kumar*





# J N GUPTA & CO

Chartered Accountants

1505, Bianca Apartment, Gundavali Azad Road,  
Andheri East, Mumbai-400069  
Contact No. 7208358784, 9001893895  
Email: [jnguptaca@icai.org](mailto:jnguptaca@icai.org)



## LIMITED REVIEW REPORT ON UNAUDITED HALF YEARLY CONSOLIDATED FINANCIAL RESULTS OF COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

TO,

**The Board of Directors of  
Adeshwar Meditex Limited,**

We have reviewed the accompanying statement of unaudited financial results of Adeshwar Meditex Limited for the half year ended September 30, 2022, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. This statement- is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagements (RE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized practice and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For M/s J N Gupta & Co.  
Chartered Accountants**

 Digitally signed by  
Jagdish Narain Gupta  
Date: 2022.11.04  
12:50:15 +05'30'

**CA. Jagdish Narain Gupta  
Partner**

M. No: 400438  
FRN: 006569C  
UDIN: 22400438BCAJMR3122  
Place: Mumbai  
Date: 04<sup>th</sup> November, 2022





**Adeshwar Meditex Limited**  
**CIN : U52390MH2007PLC169544**  
**Unaudited Statement of Consolidated assets and Liabilities As At 30th Sep, 2022**

	(Rs. in Lakhs)	
Particulars	30th Sep 2022 (Amount in `)	31st March 2022 (Amount in `)
<b>I. EQUITY AND LIABILITIES</b>		
<b>(1) Shareholder's Funds</b>		
(a) Share Capital	1,443.14	1,443.14
(b) Surplus	1,760.98	1,652.24
<b>(2) Non-current liabilities</b>		
(a) Long-Term Borrowings	308.39	407.14
(b) Other Long Term Liabilities	3.78	12.17
(c) Long Term Provision	33.93	33.93
<b>(3) Current liabilities</b>		
(a) Short-Term Borrowings		
(b) Trade Payables	1414.85	1,317.33
(A) Total Outstanding Dues of Micro Enterprises and Small Enterprises; and	-	-
(B) Total Outstanding Dues of Creditors Other Than Micro Enterprises and Small Enterprises	1,698.70	2,082.71
(c) Other Current Liabilities	204.62	298.99
(d) Short-Term Provisions	28.00	9.53
<b>Total</b>	<b>6,896.39</b>	<b>7,257.18</b>
<b>II. Assets</b>		
<b>(1) Non-Current Assets</b>		
<b>(a) Property, Plant and Equipment and Intangible Assets</b>		
<b>(i) Property, Plant and Equipment</b>		
(iii) Capital work-in-progress	328.08	302.99
(b) Non-Current Investments		
(c) Long Term Loans and Advances	10.01	10.01
(d) Deferred Tax Asset (Net)	101.56	89.90
(e) Other Non-Current Assets	12.31	12.31
	288.46	332.01
<b>(2) Current Assets</b>		
(a) Inventories		
(b) Trade Receivables	2,230.08	2,530.07
(c) Cash and Cash Equivalents	3,216.78	3,248.34
(d) Short-Term Loans and Advances	183.00	192.10
(e) Other Current Assets	513.13	526.70
	12.98	12.75
<b>Total</b>	<b>6,896.39</b>	<b>7,257.18</b>

For & On Behalf of the Board  
For Adeshwar Meditex Limited

*Siddharth Talati*

Siddharth Talati  
Managing Director

DIN : 01748038

Date: 04-11-2022





**Adeshwar Meditex Limited**

**CIN : U52390MH2007PLC169544**

**Statement Of Unaudited Consolidated Financial Results For The Half Year And Year Ended 30th September 2022**

Particulars	(Rs. in Lakhs)		
	Half Year Ended 30.09.2022 (Unaudited)	Half Year Ended 30.09.2021 (Unaudited)	Year Ended 31.03.2022 (Audited)
Revenue From Operations	4,605.55	3,021.12	6,475.54
Other Income	8.23	2.22	22.90
<b>Total Income</b>	<b>4,613.78</b>	<b>3,023.34</b>	<b>6,498.44</b>
<b>Expenses:</b>			
Cost of Materials Consumed	3,612.54	2,732.33	5,679.94
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	314.07	(208.32)	(190.66)
Employee Benefit Expense	99.33	87.92	215.24
Finance Costs	103.55	101.90	202.63
Depreciation and Amortisation Cost	25.78	16.64	38.20
Other Expenses	307.77	200.68	433.98
<b>Total Expenses</b>	<b>4,463.04</b>	<b>2,931.15</b>	<b>6,379.33</b>
<b>Profit Before Prior Period Items ,Exceptional and Extraordinary Items and Tax</b>	<b>150.74</b>	<b>92.19</b>	<b>119.11</b>
<b>Prior Period Item</b>			
Depreciation	-	-	-
Gratuity	-	-	-
<b>Tax Expense:</b>			
(1) Current Tax	42.00	23.97	39.00
(2) Deferred Tax	-	-	0.82
<b>Profit From The Period</b>	<b>108.74</b>	<b>68.22</b>	<b>79.29</b>
<b>Profit/(Loss) For The period</b>	<b>108.74</b>	<b>68.22</b>	<b>79.29</b>
<b>Earning Per Equity Share:</b>			
Face Value Per Equity Shares Rs.10/- Fully Paid up.			
(1) Basic	0.75	0.54	0.55
(2) Diluted	0.75	0.54	0.59

For & On Behalf of the Board  
For Adeshwar Meditex Limited



*Siddharth Talati*

**Siddharth Talati**  
Managing Director  
DIN : 01748038  
Date: 04-11-2022



**Adeshwar Meditex Limited**  
CIN : U52390MH2007PLC169544  
Unaudited Consolidated Cash Flow Statement For The Period Ended Sep 30, 2022

	(Rs. in Lakhs)	
Particulars	For the Period Ended 30th Sep 2022	For the Year ended March 31, 2022
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>		
Net profit before tax and extraordinary items	150.74	119.11
Adjustments for:		
Depreciation and amortisation expense	25.78	38.20
Interest Paid	103.55	191.37
Interest Received	(8.23)	(18.81)
Long Term Provision For Gratuity	-	6.17
Share Issue Expenses	-	10.88
Operating profit / (loss) before working capital changes	271.84	346.93
<b>Changes in working capital:</b>		
Increase / (Decrease) in Inventories	299.99	80.67
Increase / (Decrease) in Payables	(384.01)	288.09
Increase / (Decrease) in Receivables	31.56	(521.85)
Increase / (Decrease) in Short Term Provision	18.47	(4.69)
(Increase) / Decrease in Other current Liabilities	(94.37)	28.20
(Increase) / Decrease in Other Current Assets	(0.23)	31.27
(Increase) / Decrease in Other Non-Current Assets	43.54	(127.30)
Increase / (Decrease) in Short Term Loans and Advances	13.57	(308.69)
<b>CASH FLOW FROM / (USED IN) OPERATING ACTIVITIES</b>	<b>(71.47)</b>	<b>(534.31)</b>
Less: Taxes paid	200.37	(187.38)
Less: Taxes for Earlier Years	42.00	39.00
<b>NET CASH FLOW FROM / (USED IN) OPERATING ACTIVITIES</b>	<b>-</b>	<b>17.13</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>	<b>158.37</b>	<b>(243.51)</b>
Purchase of tangible / intangible assets	(50.88)	(117.18)
(Increase) / Decrease in long term loan and advances	(11.66)	(15.60)
(Increase) / Decrease in non-current investments	0.00	(1.40)
Dividend/ bank interest received	8.23	18.81
Investment in WOS	-	(0.21)
<b>NET CASH FLOW FROM / (USED IN) INVESTING ACTIVITIES</b>	<b>(54.31)</b>	<b>(115.57)</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>		
Interest expenses	(103.55)	(191.37)
Changes in Long Term Borrowing	(98.75)	(128.65)
Proceeds from Share Capital	-	975.00
Changes in Short Term Borrowing	97.52	(186.59)
Share Issue Expenses	-	(10.88)
Changes in Other Long Term Liabilities	(8.39)	(13.03)
<b>NET CASH FLOW FROM / (USED IN) FINANCING ACTIVITIES</b>	<b>(113.18)</b>	<b>444.47</b>
<b>NET INCREASE / (DECREASE) IN CASH &amp; CASH EQUIVALENTS (A+B+C)</b>	<b>(9.10)</b>	<b>85.39</b>
Cash and Cash equivalents at beginning period (Refer Note 14)	192.10	106.71
Cash and Cash equivalents at end of period (Refer Note 14)	183.00	192.10
<b>D. Cash and Cash equivalents comprise of</b>		
Cash on hand	0.14	0.88
<b>Balances with banks</b>		
In current accounts	182.86	191.22
<b>Total</b>	<b>183.00</b>	<b>192.10</b>

This Cash Flow Statement has been prepared as per "Indirect Method" as prescribed by Accounting Standard -3 (revised) "Cash Flow Statements"

For & On Behalf of the Board

For Adeshwar Meditex Limited

*Siddharth Talati*

Siddharth Talati  
Managing Director

DIN : 01748038

Date: 04-11-2022





## Notes

1. The unaudited financial results were reviewed by the Audit Committee and taken on record by the Board of directors at their meeting held on 04th November, 2022.
2. As required under Regulation 33 of the SEBI (LODR) Regulations, 2015, the Statutory Auditors have issued Limited Review Reports on the aforesaid unaudited financial results for the half year ended 30th September, 2022, which were also approved by the Audit Committee and Board at their meeting held on 04th November, 2022.
3. The Earning Per Sare (EPS) has been computed in accordance with the Accounting Standard on Earnings Per Share (AS 20).
4. The company is engaged in the Manufacturer and Trader of Medical Dressings, Bandages, Face Mask and PPE kits.
5. As per MCA Notification dated 16\* February 2015, companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the compulsory requirement of adoption of IND-AS. As the company is covered under the exempted category, it has not adopted IND-AS for preparation of financial results.
6. The company has issued and allotted 39,00,000 equity share of Rs. 10/- each at a price of Rs.25/- per share through an Initial Public Offer aggregating to Rs. 975 lakhs. The net issue proceeds, after excluding Expenses is 933.26 lakhs. The details of utilization of net IPO Proceeds is Mentioned Below,

Particulars	As per Prospectus	Actual Utilization (as on 30.09.2022)	Pending for utilization
Part Repayment of Loans	200.00	200.00	-
Funding Working Capital Requirement	527.00	527.00	-
General Corporate Purpose	206.26	206.26	-
Total	933.26	933.26	-

7. Figures of Previous year/Period have been regrouped/recast wherever necessary, in order to make comparable.

*Secretary*

